Details of the Drug

General Information of Drug (ID: DM7GCVW)

Drug Name
Acalabrutinib
Synonyms
Calquence; UNII-I42748ELQW; I42748ELQW; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Calquence (TN); Acalabrutinib(ACP196); Acalabrutinib (ACP-196); GTPL8912; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; WDENQIQQYWYTPO-IBGZPJMESA-N; KS-000006AT; KS-000006AD; s8116; BDBM50175583; AKOS030526094; ZINC208774715; DB11703; CS-5356; DS-3326
Indication
Disease Entry ICD 11 Status REF
Mantle cell lymphoma 2A85.5 Approved [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 3 [2]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 465.5
Topological Polar Surface Area (xlogp) 3
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
Chemical Identifiers
Formula
C26H23N7O2
IUPAC Name
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
Canonical SMILES
CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
InChI
InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
InChIKey
WDENQIQQYWYTPO-IBGZPJMESA-N
Cross-matching ID
PubChem CID
71226662
CAS Number
1420477-60-6
DrugBank ID
DB11703
TTD ID
D09PQZ
INTEDE ID
DR0031
ACDINA ID
D00005

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase BTK (ATK) TTGM6VW BTK_HUMAN Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [3]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Mantle cell lymphoma
ICD Disease Classification 2A85.5
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine-protein kinase BTK (ATK) DTT BTK 3.54E-01 0.24 0.56
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 1.34E-01 -2.79E-01 -7.05E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.81E-01 2.72E-01 6.95E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Acalabrutinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Acalabrutinib caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [29]
Arn-509 DMT81LZ Major Increased metabolism of Acalabrutinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [29]
Troleandomycin DMUZNIG Major Decreased metabolism of Acalabrutinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [29]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Acalabrutinib caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [29]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Acalabrutinib caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [29]
MK-8228 DMOB58Q Major Decreased metabolism of Acalabrutinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [29]
Tazemetostat DMWP1BH Moderate Increased metabolism of Acalabrutinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [29]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Acalabrutinib and Avapritinib. Gastrointestinal stromal tumour [2B5B] [29]
Brigatinib DM7W94S Moderate Increased metabolism of Acalabrutinib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [29]
PF-06463922 DMKM7EW Moderate Increased metabolism of Acalabrutinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [29]
Selpercatinib DMZR15V Moderate Decreased metabolism of Acalabrutinib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [29]
IPI-145 DMWA24P Major Decreased metabolism of Acalabrutinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [29]
Arry-162 DM1P6FR Major Increased risk of bleeding by the combination of Acalabrutinib and Arry-162. Melanoma [2C30] [29]
LGX818 DMNQXV8 Major Increased risk of bleeding by the combination of Acalabrutinib and LGX818. Melanoma [2C30] [29]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Acalabrutinib and Siponimod. Multiple sclerosis [8A40] [30]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Acalabrutinib and Ocrelizumab. Multiple sclerosis [8A40] [31]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Acalabrutinib and Ozanimod. Multiple sclerosis [8A40] [32]
Fedratinib DM4ZBK6 Major Decreased metabolism of Acalabrutinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [29]
Entrectinib DMMPTLH Moderate Decreased metabolism of Acalabrutinib caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [29]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Acalabrutinib caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [29]
Abametapir DM2RX0I Moderate Decreased metabolism of Acalabrutinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [33]
Lefamulin DME6G97 Moderate Decreased metabolism of Acalabrutinib caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [34]
Voxelotor DMCS6M5 Major Decreased metabolism of Acalabrutinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [29]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Acalabrutinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [29]
Larotrectinib DM26CQR Moderate Decreased metabolism of Acalabrutinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [29]
LEE011 DMMX75K Major Decreased metabolism of Acalabrutinib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [29]
Elagolix DMB2C0E Moderate Increased metabolism of Acalabrutinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [29]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Acalabrutinib and Betrixaban. Venous thromboembolism [BD72] [29]
⏷ Show the Full List of 28 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Acalabrutinib 100 mg capsule 100 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
4 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
5 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
6 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
7 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
8 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
9 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
10 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
11 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
14 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
15 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
16 Drug Interactions Flockhart Table
17 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
18 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
19 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
20 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
21 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
23 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
25 Clinical pipeline report, company report or official report of InnoCare Pharma.
26 Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
27 Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
28 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
29 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
30 Cerner Multum, Inc. "Australian Product Information.".
31 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
32 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
33 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
34 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.